# TADLIQ
> **NDA214522** · New Drug Application · Sponsor: CMP DEV LLC · Approved 2022-06-17
## Drug
- **FDA Application Number:** NDA214522
- **Application type:** New Drug Application
- **Brand name:** TADLIQ
- **Generic name:** TADALAFIL
- **Active ingredients:** TADALAFIL
- **Dosage form:** SUSPENSION
- **Route:** ORAL
- **Marketing status:** Prescription
- **Sponsor:** CMP DEV LLC
- **Manufacturer:** CMP Pharma, Inc.
- **First approval:** 2022-06-17
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214522)
---
*AI Analytics · CC0 1.0*